Core Viewpoint - China Tongru (01763) experienced a significant stock price increase of over 7% during trading, attributed to the launch of high-purity 13CO gas and urea products, marking a shift towards self-sufficiency in the medical stable isotope carbon sector [1] Company Overview - China Tongru is a specialized company under China National Nuclear Corporation, focusing on nuclear technology applications, including the development, production, and sales of nuclear medicine, radiation source products, and related services [1] - The company has established a comprehensive layout in the nuclear medicine field, with a network of 37 medical centers and 7 R&D production bases by December 31, 2024, positioning itself as a leader in China's nuclear medicine sector [1] Industry Impact - The launch of high-purity 13CO gas and urea products signifies China's ability to break free from reliance on imported materials for urea breath diagnostic agents, achieving full control over the entire industry chain from key raw materials to end products [1] - This development enhances the company's status as a leading enterprise capable of managing the complete supply chain for breath test products in the medical stable isotope carbon field [1]
港股异动 | 中国同辐(01763)盘中涨超7% 公司发布高丰度13CO气体及尿素产品 助力产业链全面自主可控